{"id":"course-b3-vin","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL5747693","moleculeType":null,"molecularWeight":"378.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy combination where vincristine acts as a vinca alkaloid that inhibits microtubule formation, preventing mitotic spindle assembly and causing cell cycle arrest. The 'Course B3' component likely refers to a standardized protocol block used in pediatric cancer treatment regimens, combining vincristine with additional chemotherapeutic agents to achieve synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Course B3 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents to disrupt cancer cell division and induce apoptosis in pediatric malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:42.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric acute lymphoblastic leukemia (ALL)"},{"name":"Pediatric lymphomas and other hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Course B3 +Vin","genericName":"Course B3 +Vin","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Course B3 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents to disrupt cancer cell division and induce apoptosis in pediatric malignancies. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric lymphomas and other hematologic malignancies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}